Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jun;17(6):854-61.
doi: 10.1093/neuonc/nou348. Epub 2015 Jan 13.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

James Schuster  1 , Rose K Lai  1 , Lawrence D Recht  1 , David A Reardon  1 , Nina A Paleologos  1 , Morris D Groves  1 , Maciej M Mrugala  1 , Randy Jensen  1 , Joachim M Baehring  1 , Andrew Sloan  1 , Gary E Archer  1 , Darell D Bigner  1 , Scott Cruickshank  1 , Jennifer A Green  1 , Tibor Keler  1 , Thomas A Davis  1 , Amy B Heimberger  1 , John H Sampson  1
Affiliations
Clinical Trial

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

James Schuster et al. Neuro Oncol. 2015 Jun.

Abstract

Background: The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term survival. Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhole limpet hemocyanin. In previous phase II trials (ACTIVATE/ACT II), rindopepimut was well tolerated with robust EGFRvIII-specific immune responses and promising progression-free and overall survival. This multicenter, single-arm phase II clinical trial (ACT III) was performed to confirm these results.

Methods: Rindopepimut and standard adjuvant temozolomide chemotherapy were administered to 65 patients with newly diagnosed EGFRvIII-expressing (EGFRvIII+) glioblastoma after gross total resection and chemoradiation.

Results: Progression-free survival at 5.5 months (∼8.5 mo from diagnosis) was 66%. Relative to study entry, median overall survival was 21.8 months, and 36-month overall survival was 26%. Extended rindopepimut vaccination (up to 3.5+ years) was well tolerated. Grades 1-2 injection site reactions were frequent. Anti-EGFRvIII antibody titers increased ≥4-fold in 85% of patients, and increased with duration of treatment. EGFRvIII was eliminated in 4/6 (67%) tumor samples obtained after >3 months of therapy.

Conclusions: This study confirms, in a multicenter setting, the preliminary results seen in previous phase II trials of rindopepimut. A pivotal, double-blind, randomized, phase III trial ("ACT IV") is under way.

Keywords: ACT III; EGFRvIII; glioblastoma; glioma; rindopepimut.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Anti-EGFRvIII antibody titers. Antibody titers to EGFRvIII were measured by enzyme-linked immunosorbent assay as described under Methods. Each point represents an individual patient titer, while horizontal lines delineate the mean for that time point.
Fig. 2.
Fig. 2.
Kaplan–Meier estimates of PFS and OS. Survival durations are calculated from study entry, representing a median of 3.0 (range, 2.4–4.4) months from diagnosis (as shown in Table 1). Line markers represent censored data.
Fig. 3.
Fig. 3.
Kaplan–Meier estimates of PFS and OS, by MGMT promoter methylation status. (A) PFS and (B) OS are calculated from study entry, representing a median of 3.0 (range, 2.4–4.4) months from diagnosis (as shown in Table 1). Line markers represent censored data. HR, hazard ratio; NE, not estimated.
Fig. 4.
Fig. 4.
Kaplan–Meier estimates of PFS and OS for phase II rindopepimut studies. (A) PFS and (B) OS are calculated from diagnosis. Line markers represent censored data. In the 3 rindopepimut studies (ACTIVATE, ACT II, and ACT III), rindopepimut vaccinations began ∼3 mo after diagnosis.
See this image and copyright information in PMC

Comment in

References

    1. Humphrey PA, Wong AJ, Vogelstein B, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A. 1990;8711:4207–4211. - PMC - PubMed
    1. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 1997;2725:2927–2935. - PubMed
    1. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;2516:2288–2294. - PubMed
    1. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;6320:6962–6970. - PubMed
    1. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;114:1462–1466. - PubMed

Publication types

MeSH terms